PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1252694
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1252694
Anticoagulant Reversal Drugs Market size was valued at USD 780.5 Million in 2022, expanding at a CAGR of 15.5% from 2023 to 2030.
Anticoagulant drugs, also known as blood thinners, are drugs that reduce or prevent blood coagulation and are frequently used to treat thrombosis. Drugs used to reverse the effects of anticoagulants, such as Idarucizumab, are administered when a bleeding complication or anticoagulant overdose develops. In some circumstances, such as unexpected surgery, anticoagulant therapy overdoses, and uncontrolled bleeding, anticoagulant reversal medications are necessary to counteract the effects of anticoagulation.
People are now more likely to have bleeding problems than before. One of the most prevalent diseases, gastrointestinal (GI) hemorrhage accounts for about 50% of major bleeding episodes. Another serious condition that is getting more common among DOAC patients is intracranial bleeding (ICH). (Direct-acting Oral Anticoagulants). In addition, a rise in the geriatric population, a rise in sedentary lifestyle adoption, and an increase in heart attack instances all contribute to the market's expansion. The frequency of bleeding disorders that lead to abnormal blood coagulation, such as atrial fibrillation (AFib), Von Willebrand disease (VWD), anemia, and others are also rising, which in turn increases the demand for anticoagulant reversal drugs.
Globally, healthcare infrastructure changes and ongoing technological advancements are setting the standard. This is primarily attributable to the outstanding R&D projects carried out by prestigious companies to successfully renovate and enhance the laboratory clinics for various drug discovery and drug testing processes. The U.S. Centers for Medicare and Medicaid Services (CMS) have given specific medications that are specifically made to interact with a few anticoagulants the new technology add-on payment (NTAP) designation. The patient's access to medications with supplemental Medicare reimbursement in hospitals and clinics is significantly improved by this classification.
Anticoagulant Reversal Drugs Market- Segment Analysis
Based on the product, the idarucizumab segment is expected to dominate the market during the forecast period. Idarucizumab's strong revenue generation in important regions is responsible for this. The market is divided into prothrombin complex concentrates, phytonadione (vitamin K), andexanet alfa, idarucizumab, protamine, and others based on the sort of product.
Based on the distribution channel, the hospital segment is expected to dominate the market during the forecast period. This is explained by the fact that hospitals are the primary facilities for the detection and management of various kinds of bleeding disorders. The segment is being driven even more by uncontrolled bleeding in emergencies.
North America is expected to dominate the market during the forecast period. The rising number of surgeries, the increase in the geriatric population, and the region's favorable approval of drugs for life-threatening bleeding disorders are the primary drivers of this market's expansion. Additionally, there are improved healthcare infrastructure options available, and leading market players are doing more R&D. Moreover, during the forecast period, the market for anticoagulant reversal drugs will grow due to high healthcare spending and patient-friendly reimbursement policies for expensive or unaffordable medications.
In March 2022, for patients taking the Factor Xa inhibitors rivaroxaban, apixaban, or edoxaban, where reversal of anticoagulation is crucial due to lethal or excessive bleeding, Ondexxya became the first reversal agent to be authorized in Japan. The Japanese Ministry of Health, Labour, and Welfare approved the drug as a result of the encouraging findings from the ANNEXA-4 Phase III clinical trial, which showed Ondexxya significantly reversed anti-FXa activity in patients who experienced fatal bleeding. Japan also made history by facilitating Ondexxya's full regulatory clearance for use. This offers a significant improvement in the diagnosis of hospitalized patients with pernicious bleeding.
This proposed research study on the Anticoagulant Reversal Drugs market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains an attractive investment proposition matrix for ` the Anticoagulant Reversal Drugs market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain the Anticoagulant Reversal Drugs market
The impact of COVID-19 on the Anticoagulant Reversal Drugs market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight into the Anticoagulant Reversal Drugs market post-COVID will also be covered.
To give the users of this report a comprehensive view of the Anticoagulant Reversal Drugs market, we have also included a competitive landscape and key innovator analysis for the Anticoagulant Reversal Drugs market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand the financial information and strategic initiatives of players operating in the Anticoagulant Reversal Drugs market.
In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launches, research & development, and regional expansion of major participants involved in the market on global as well as regional levels.
The global Anticoagulant Reversal Drugs market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
The scope of this report covers the market by its major segments, which include as follows:
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
Dr. Reddy's Laboratories Ltd
Teva Pharmaceutical Industries Ltd
Endo International plc
Sun Pharmaceutical Industries Ltd
Novartis AG
Mylan N.V.
Lupin
Cipla Inc
Aurobindo Pharma
Sanofi
Merck & Co. Inc
Amneal Pharmaceuticals LLC.
Alvogen
Prothrombin Complex Concentrates
Phytonadione
Andexanet Alfa
Idarucizumab
Protamine
Others
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA